BMC pulmonary medicine
Clinical efficacy and cost-effectiveness of mepolizumab for COPD with type 2 inflammation.
Jefferson Antonio Buendía, Diana Guerrero Patiño, Oscar Muñoz Mejia, Carlos Celis Preciado
Published: 202610.1186/s12890-025-04099-6
No abstract available for this study.